MoonLake Immunotherapeutics (NASDAQ: MLTX) Employee Directory

Biotechnology ResearchSwitzerland51-200 Employees

MoonLake Immunotherapeutics AG is a clinical-stage biopharmaceutical company leveraging revolutionary Nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Find MoonLake Immunotherapeutics (NASDAQ: MLTX) employees' phone numbers or email addresses

MoonLake Immunotherapeutics (NASDAQ: MLTX) Global Highlights

Europe
119

United Kingdom Of Great Britain And Northern Ireland
54
Portugal
33
Switzerland
27
Belgium
2
France
1
Ireland
1
Germany
1

MoonLake Immunotherapeutics (NASDAQ: MLTX)'s Leadership

M. B.
Chief Financial Officer
Mobile Phone
Email
O. D.
Chief Technical Officer
Mobile Phone
Email
W. O. B.
Chief Medical Officer
Mobile Phone
Email
N. B.
Chief Clinical Development Officer
Mobile Phone
Email
T. A.
Vp Marketing, Market Access & Pricing
Mobile Phone
Email
E. C.
Vice President Medical Affairs And Translational Research
Mobile Phone
Email
J. F. M.
Vice President Clinical Development
Mobile Phone
Email
J. S. D. S.
Founder & Chief Executive Officer
Mobile Phone
Email

Contact profiles from MoonLake Immunotherapeutics (NASDAQ: MLTX)

Name

Title

Contact Info

Location

Last Update

J. C.
Associate Vice President
Mobile Phone
Email
PortugalPorto
Nov 13, 2025
J. F. M.
Vice President Clinical Development
Mobile Phone
Email
PortugalPorto District
Sep 02, 2025
J. S.
Associate Director Hrbp & Operations
Mobile Phone
Email
United KingdomEngland
Nov 06, 2025
J. S.
Senior Director Marketing, Market Access & Pricing
Mobile Phone
Email
SwitzerlandZurich
Oct 07, 2025
A. P.
Senior Director Clinical Operations
Mobile Phone
Email
PortugalPorto District
Oct 31, 2025
T. T.
Associate Director, Corporate Development
Mobile Phone
Email
SwitzerlandZurich
Nov 10, 2025
T. O.
Senior Medical Director
Mobile Phone
Email
United Kingdom
Oct 25, 2025
N. A.
Senior Director Global Medical Affairs
Mobile Phone
Email
United KingdomEngland
Oct 07, 2025
A. J.
Senior Director Clinical Operations
Mobile Phone
Email
United Kingdom
Oct 17, 2025
L. W.
Associate Director Clinical Operations
Mobile Phone
Email
United Kingdom
Oct 23, 2025

Frequently Asked Questions

What is MoonLake Immunotherapeutics (NASDAQ: MLTX) known for?

MoonLake Immunotherapeutics (NASDAQ: MLTX) was founded in 2021 operates in the Biotechnology Research industry. The company's main headquarters is located in Dorfstrasse, 29 Zug, Zug 6300, CH. Explore MoonLake Immunotherapeutics (NASDAQ: MLTX)'s company overview page for more information.

What is MoonLake Immunotherapeutics (NASDAQ: MLTX)'s most common email format?

MoonLake Immunotherapeutics (NASDAQ: MLTX) employees' email format typically follows the pattern of . Trying to find reliable and up-to-date employee contact data? Find more MoonLake Immunotherapeutics (NASDAQ: MLTX) email formats with LeadIQ.

How many employees does MoonLake Immunotherapeutics (NASDAQ: MLTX) have currently?

MoonLake Immunotherapeutics (NASDAQ: MLTX) has approximately 138 employees as of October 2025. These team members are located across 1 continents, including Europe.

Who are MoonLake Immunotherapeutics (NASDAQ: MLTX)'s key employees and leadership?

As of October 2025, MoonLake Immunotherapeutics (NASDAQ: MLTX)'s key employees include:

Chief Financial Officer: M. B.
Chief Technical Officer: O. D.
Chief Medical Officer: W. O. B.
Chief Clinical Development Officer: N. B.
Vp Marketing, Market Access & Pricing: T. A.

Looking for contact data? Unlock accurate emails and phone numbers for your ideal prospects with LeadIQ.

Everything for prospecting,
in one platform.

What you can expect from LeadIQ:

B2B data verified in real-time
Sync data to your CRM, & add it to an outreach sequence in one click
Integrations with your tech stack for optimal efficiency
A patented AI cold email generator
Account & contact-level job change tracking

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.